Overview:

Immunotherapy is reshaping the treatment landscape across the entire small cell lung cancer (SCLC) continuum, from limited-stage through relapsed disease. Three FDA approvals in the past 15 months—durvalumab consolidation after concurrent chemoradiotherapy in limited-stage SCLC (LS-SCLC), lurbinectedin plus atezolizumab as first-line maintenance in extensive-stage SCLC (ES-SCLC), and tarlatamab for relapsed disease—have introduced practice-changing options after decades of limited progress. As these therapies enter routine practice, it is vital for clinicians to stay current on the evolving clinical efficacy data, understand the distinctions between available regimens, and recognize the unique safety profiles and toxicity management strategies—including immune-mediated adverse events, cytokine release syndrome (CRS), and immune effector cell–associated neurotoxicity syndrome (ICANS)—associated with each approach.

This program pairs an academic SCLC expert with a community oncologist to discuss the latest advances and enable the integration of immunotherapy across the SCLC continuum into community practice. Through interactive, case-based discussions between academic and community oncology colleagues, participants will gain practical insights and strategies to identify appropriate candidates for consolidation immunotherapy in limited-stage disease, navigate frontline chemoimmunotherapy backbone and maintenance decisions in extensive-stage disease, develop evidence-based sequencing approaches for relapsed SCLC, and proactively recognize and manage treatment-related adverse events to optimize patient outcomes.

Learning Objectives:

Upon completion of this activity, learners will be better able to:

• Integrate consolidation immunotherapy into the management of patients with LS-SCLC who have not progressed after concurrent chemoradiotherapy.
• Evaluate the clinical implications of frontline immunotherapy–chemotherapy backbone selection in ES-SCLC.
• Develop an evidence-based sequencing strategy for relapsed SCLC based on prior treatment history and disease characteristics.

Target Audience:

This educational program is primarily directed toward community-based medical oncologists, radiation oncologists, nurses, NPs/APPs, and other health care professionals involved in the treatment of patients with small cell lung cancer.

Accreditation/Credit Designation:

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours. 

Acknowledgment of Educational Support

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Have a question for the PER® team?

Oncology Inquiries: onc-info@gotoper.com

Eye Care Inquiries: eye-info@gotoper.com

Multispecialty Inquiries: multi-info@gotoper.com